NASDAQ:TYME

Tyme Technologies Stock Forecast, Price & News

$1.12

+0.05 (+4.67 %)

(As of 12/2/2020 04:31 PM ET)

Add

Compare

Today's Range

$1.02

Now: $1.12▼

$1.15

50-Day Range

$0.87

MA: $0.96▼

$1.05

52-Week Range

$0.85

Now: $1.12▼

$2.04

Volume796,926 shs

Average Volume663,830 shs

Market Capitalization$145.79 million

P/E RatioN/A

Dividend YieldN/A

Beta0.84

Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Tyme Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.50, Tyme Technologies has a forecasted upside of 779.6% from its current price of $1.08.
Amount of Analyst Coverage
Tyme Technologies has received no research coverage in the past 90 days.

2.4 Community Rank

Outperform Votes
Tyme Technologies has received 197 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Tyme Technologies has received 208 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Tyme Technologies has received 51.36% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote “Outperform” if you believe TYME will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Tyme Technologies does not currently pay a dividend.
Dividend Growth
Tyme Technologies does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tyme Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $430,345.00 in company stock.
Percentage Held by Insiders
Only 25.51% of the stock of Tyme Technologies is held by insiders.
Percentage Held by Institutions
Only 14.00% of the stock of Tyme Technologies is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Tyme Technologies are expected to grow in the coming year, from ($0.28) to ($0.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tyme Technologies is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tyme Technologies is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tyme Technologies has a P/B Ratio of 7.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.31 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TYME

Previous Symbol

CUSIPN/A

CIK1537917

Webwww.tymeinc.com

Phone212-461-2315

Employees18

Debt

Debt-to-Equity RatioN/A

Current Ratio3.96

Quick Ratio3.96

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.15 per share

Price / Book7.47

Profitability

EPS (Most Recent Fiscal Year)($0.17)

Net Income$-22,000,000.00

Net MarginsN/A

Return on Equity-217.29%

Return on Assets-114.20%

Miscellaneous

Outstanding Shares130,172,000

Market Cap$145.79 million

Next Earnings Date2/3/2021 (Estimated)

OptionableOptionable

$1.12

+0.05 (+4.67 %)

(As of 12/2/2020 04:31 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter.

Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

How has Tyme Technologies' stock price been impacted by COVID-19 (Coronavirus)?

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TYME shares have increased by 4.8% and is now trading at $1.10.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Tyme Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tyme Technologies or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Tyme Technologies?

Wall Street analysts have given Tyme Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tyme Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Tyme Technologies.

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) posted its earnings results on Thursday, November, 12th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02.
View Tyme Technologies' earnings history.

What price target have analysts set for TYME?

2 brokerages have issued twelve-month price objectives for Tyme Technologies' shares. Their forecasts range from $9.50 to $9.50. On average, they anticipate Tyme Technologies' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 763.6% from the stock's current price.
View analysts' price targets for Tyme Technologies.

Who are some of Tyme Technologies' key competitors?

Some companies that are related to Tyme Technologies include XBiotech (XBIT), Ardelyx (ARDX), SIGA Technologies (SIGA), Neoleukin Therapeutics (NLTX), 89bio (ETNB), Aprea Therapeutics (APRE), Graybug Vision (GRAY), RAPT Therapeutics (RAPT), Pandion Therapeutics (PAND), Rigel Pharmaceuticals (RIGL), Urovant Sciences (UROV), CymaBay Therapeutics (CBAY), Avid Bioservices (CDMO), Merus (MRUS) and Marinus Pharmaceuticals (MRNS).
View all competitors.

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:

Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 57, Pay $900.79k)
Mr. Ben R. Taylor, Advisor (Age 43, Pay $710.98k)
Ms. Barbara C. Galaini, Acting Principal Financial Officer, Principal Accounting Officer & Corp. Controller (Age 62)
Brian Gill, Head of Corp. Communications & IR
Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 56)
Dr. Giuseppe Del Priore, Chief Medical Officer (Age 58)
Dr. Jonathan M. Eckard, Chief Bus. Officer (Age 46)
Mr. John Zucaro P.E., Sr. VP of CMC
Dr. John M. Rothman, Exec. VP of Product Devel. (Age 72)

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Who are Tyme Technologies' major shareholders?

Tyme Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (0.12%) and JPMorgan Chase & Co. (0.03%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michael Demurjian, Michele Ilene Korfin and Steve Hoffman.
View institutional ownership trends for Tyme Technologies.

Which major investors are selling Tyme Technologies stock?

TYME stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. Company insiders that have sold Tyme Technologies company stock in the last year include Michael Demurjian, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies.

Which major investors are buying Tyme Technologies stock?

TYME stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michele Ilene Korfin, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies.

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $1.10.

How big of a company is Tyme Technologies?

Tyme Technologies has a market capitalization of $143.19 million. The company earns $-22,000,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Tyme Technologies employs 18 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is www.tymeinc.com.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings